What is Nuwellis, Inc. (NUWE) stock price today?

Nuwellis, Inc. (NUWE) is currently trading at $0.69, up 2.06% today.

What is NUWE P/E ratio?

Nuwellis, Inc.'s P/E ratio is -0.01. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is NUWE return on equity (ROE)?

Nuwellis, Inc.'s return on equity (ROE) is -605.75%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Nuwellis, Inc.'s market cap?

Nuwellis, Inc. has a market capitalization of $2.51M.

NASDAQ · Medical - Devices

Nuwellis, Inc. (NUWE) Stock

$0.69 +2.06% NASDAQ: NUWE Healthcare

Valuation

Metric	Value
Price	$0.69
Market Cap	$2.51M
P/E Ratio	-0.01
P/B Ratio	-0.06
P/S Ratio	0.28
EPS (TTM)	$-25.39
52-Week High	$172.90
52-Week Low	$0.68
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-605.75%
ROA	-121.85%
ROCE	-247.64%
Gross Margin	-137.50%
Operating Margin	-137.50%
Net Margin	-123.38%
Debt/Equity	-0.10
Current Ratio	1.67

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$8.0M	$9.0M	$9.0M	$9.0M	$8.0M
Operating Profit	$-20.0M	$-17.0M	$-18.0M	$-11.0M	$-11.0M
Net Profit	$-20.0M	$-15.0M	$-20.0M	$-11.0M	$-18.0M
EPS	$-350143.15	$-102268.25	$-12602.45	$-280.00	$-25.39
Op Margin	-246.5%	-201.0%	-198.9%	-125.7%	-134.3%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$30.0M	$25.0M	$10.0M	$10.0M	$6.0M
Total Liabilities	$4.0M	$12.0M	$7.0M	$3.0M	$3.0M
Cash	$9.0M	$18.0M	$4.0M	$5.0M	$1.0M
Borrowings	$1.0M	$1.0M	$1.0M	$1.0M	$0

Latest News

Nuwellis Secures US Patent for Dual-Lumen Catheter Designed to Improve Extracorporeal Therapies MT Newswires · Jul 16, 2026 Nuwellis Awarded U.S. Patent for Novel Catheter Technology Designed to Enhance Extracorporeal Therapies GlobeNewswire · Jul 16, 2026 Nuwellis to Showcase Aquadex Therapy at KidneyBee Summit 2026 GlobeNewswire · Jul 7, 2026 Nuwellis Celebrates Five Years of Support of the Pediatric Cardiac Critical Care Consortium (PC⁴) GlobeNewswire · Jun 26, 2026 Nuwellis Announces Pediatric Expansion in Michigan with First Aquadex SmartFlow® Installations GlobeNewswire · Jun 25, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-18.0M	$-15.0M	$-18.0M	$-10.0M	$-11.0M
Investing Cash Flow	$-16.0M	$15.0M	$0	$0	$0
Financing Cash Flow	$0	$0	$0	$3.0M	$0
Net Cash Flow	$-6.0M	$9.0M	$-14.0M	$1.0M	$-4.0M
Free Cash Flow	$-18.0M	$-15.0M	$-18.0M	$-10.0M	$-11.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	0.16
FCF Yield	-499.73%
Quick Ratio	1.54
Interest Coverage	-1.00
Return 1Y	-98.71%
Return 3Y	-100.00%
Return 5Y	-100.00%

Ownership

Insiders Held0.01%

Institutions Held1.66%

Institutions Float Held1.66%

Institutional Holder	Shares	Report Date
Armistice Capital, LLC	6,748	2026-03-31
Geode Capital Management, LLC	1,262	2026-03-31
Tower Research Capital LLC (TRC)	148	2026-03-31
Citigroup Inc.	146	2026-03-31
SBI Securities Co., Ltd.	2	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ACONAclarion, Inc.	$2.34	+1.30%	-0.34	$6.74M	0.00%
BACKIMAC Holdings, Inc.	$0.02	+0.00%	-0.01	$79484	0.00%
BCTXWBriaCell Therapeutics Corp.	$0.00	—	0.00	$1695	0.00%
IVFINVO Fertility, Inc.	$0.73	-1.70%	-0.03	$1.30M	0.00%
NUVOHoldco Nuvo Group D.G Ltd. Ordinary Shares	$0.17	+100.00%	-0.10	$5.65M	0.00%

About Nuwellis, Inc.

Nuwellis, Inc. is led by CEO John L. Erb, employs 38 people, headquartered in US, publicly traded since 2012.

Nuwellis, Inc. (NUWE) stock trades at $0.69 with a market capitalization of $2.51M. The stock is valued at a price-to-earnings (P/E) ratio of -0.01, price-to-book of -0.06, price-to-sales of 0.28. Over the past 52 weeks the stock has ranged between $0.68 and $172.90, and currently trades 99.6% below its 52-week high.

On profitability, Nuwellis, Inc. generates a return on equity (ROE) of -605.75%, return on capital employed of -247.64%, an operating margin of -137.50%, a net profit margin of -123.38%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides